Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators

Details for Australian Patent Application No. 2004222095 (hide)

Owner Santhera Pharmaceuticals (Schweiz) GmbH

Inventors Soeberdt, Michael; Von Sprecher, Andreas; Weyermann, Philipp

Agent Spruson & Ferguson

Pub. Number AU-B-2004222095

PCT Pub. Number WO2004/083209

Priority 03006254.1 20.03.03 EP

Filing date 19 March 2004

Wipo publication date 30 September 2004

Acceptance publication date 17 May 2007

International Classifications

C07D 471/10 (2006.01) Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups

A61K 31/438 (2006.01) - the ring being spiro-condensed with carbocyclic or heterocyclic ring systems

A61K 31/454 (2006.01)

A61K 31/4545 (2006.01)

A61K 31/496 (2006.01) - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene

A61P 3/04 (2006.01) Drugs for disorders of the metabolism

A61P 15/00 (2006.01) Drugs for genital or sexual disorders

A61P 25/22 (2006.01) Drugs for disorders of the nervous system

A61P 25/24 (2006.01) Drugs for disorders of the nervous system

C07D 311/24 (2006.01) Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings

C07D 401/12 (2006.01) Heterocyclic compounds containing two or more hetero rings

C07D 401/14 (2006.01) Heterocyclic compounds containing two or more hetero rings

C07D 405/14 (2006.01) Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom

Event Publications

29 September 2005 PCT application entered the National Phase

  PCT publication WO2004/083209 Priority application(s): WO2004/083209

17 May 2007 Application Accepted

  Published as AU-B-2004222095

14 June 2007 Change of Name(s) of Applicant(s), Section 104

  Santhera Pharmaceuticals (Schweiz) GmbH The name of the applicant has been changed to Santhera Pharmaceuticals (Schweiz) AG

13 September 2007 Standard Patent Sealed

15 October 2009 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004222096-Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators

2004222090-Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators